VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Thursday, January 1, 2026

Stock Comparison

ABB Ltd vs Gilead Sciences, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

ABB Ltd

ABBN · SIX Swiss Exchange

Market cap (USD)$136.3B
SectorIndustrials
CountryCH
Data as of2025-12-31
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into ABB Ltd's moat claims, evidence, and risks.

View ABBN analysis

Gilead Sciences, Inc.

GILD · NASDAQ Global Select Market

Market cap (USD)$155.6B
SectorHealthcare
CountryUS
Data as of2025-12-30
Moat score
74/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.

View GILD analysis

Comparison highlights

  • Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 73 / 100 for ABB Ltd).
  • Segment focus: ABB Ltd has 4 segments (46.2% in Electrification); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
  • Moat breadth: ABB Ltd has 6 moat types across 3 domains; Gilead Sciences, Inc. has 8 across 3.

Primary market context

ABB Ltd

Electrification

Market

Low- and medium-voltage electrification equipment and solutions

Geography

Global

Customer

B2B/B2G

Role

Manufacturer and solutions provider; channel-led distribution; after-sales service

Revenue share

46.2%

Gilead Sciences, Inc.

HIV

Market

HIV treatment and prevention medicines (antiretroviral therapy and PrEP)

Geography

Global (U.S. and Europe are major markets)

Customer

Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies

Role

Drug developer and marketing authorization holder

Revenue share

68.5%

Side-by-side metrics

ABB Ltd
Gilead Sciences, Inc.
Ticker / Exchange
ABBN - SIX Swiss Exchange
GILD - NASDAQ Global Select Market
Market cap (USD)
$136.3B
$155.6B
Sector
Industrials
Healthcare
HQ country
CH
US
Primary segment
Electrification
HIV
Market structure
Oligopoly
Oligopoly
Market share
n/a
50%-60% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
73 / 100
74 / 100
Moat domains
Supply, Demand, Network
Demand, Legal, Supply
Last update
2025-12-31
2025-12-30

Moat coverage

Shared moat types

Brand TrustService Field Network

ABB Ltd strengths

Distribution ControlData Workflow LockinInstalled Base ConsumablesEcosystem Complements

Gilead Sciences, Inc. strengths

Habit DefaultSwitching Costs GeneralIP Choke PointCapex Knowhow ScaleCompliance AdvantageRegulated Standards Pipe

Segment mix

ABB Ltd segments

Full profile >

Electrification

Oligopoly

46.2%

Motion

Oligopoly

22%

Process Automation

Oligopoly

20.5%

Robotics & Discrete Automation

Oligopoly

9.8%

Gilead Sciences, Inc. segments

Full profile >

HIV

Oligopoly

68.5%

Oncology (Cell Therapy + Trodelvy)

Oligopoly

11.5%

Liver Disease

Oligopoly

10.6%

Veklury (Remdesivir)

Competitive

6.3%

Other Products

Competitive

3.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.